Valuation dashboard for Kymera Therapeutics, Inc. (KYMR) with P/E N/A, P/B 7.56, EV/EBITDA N/A and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins.
Analysis Summary
Kymera Therapeutics, Inc. reported revenue of $39.2M in the most recent fiscal year, growing at a 5-year CAGR of 2.9%.
Trailing-twelve-month margins: gross margin 102.0%, operating margin -333.5%, net margin -285.4%.
Balance sheet quality for KYMR: current ratio of 10.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 7.56 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.22 |
| vs Current Price | -99.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | $9.6B | 7.56 | ||
| ACLX | Arcellx, Inc. | $6.7B | 16.10 | ||
| PRAX | Praxis Precision Medicines, Inc. | $8.7B | 6.71 | -34.1% | |
| IMVT | Immunovant, Inc. | $7.5B | 9.99 | ||
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 7.52 | -44.2% | |
| NAMS | NewAmsterdam Pharma Company N.V. | $2.5B | 5.45 | -29.8% | |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.8B | 12.10 | 3.57 | 32.4% |
Price
| Price | $116.33 |
| Market Cap | $9.6B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Gross Margin | 101.98% |
| Operating Margin | -333.54% |
| Net Margin | -285.41% |
Related companies: AAPG · ACAD · ACLX · AKRO · CRNX · IMVT · NAMS
Explore sector: Healthcare · Biotechnology
More sections of KYMR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks